Should liver metastases of breast cancer be biopsied to improve treatment choice?

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2227-2233

  Curigliano, G ^a   Bagnardi, V ^b,c,d   Viale, G ^b,e   Fumagalli, L ^a   Rotmensz, N ^b   Aurilio, G ^a   Locatelli, M ^a   Pruneri, G ^b,e   Giudici, S ^a   Bellomi, M ^b,e   Della Vigna, P ^b   Monfardini, L ^b   Orsi, F ^b   Nole F ^a   Munzone, E ^a   Goldhirsch, A ^a  

^a Division of Medical Oncology   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Southern Europe   (Switzerland)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Biology of disease; Biopsy; Breast cancer; Liver metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RETROSPECTIVE STUDY; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

EID: 80053147913     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq751     Document Type: Article

References (39)

1. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
3. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20(8): 1319-1329.
4. Rosen PP, Oberman H. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology 1993.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 2002; 41: 151.
6. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20(9): 1499-1504.
7. Aitken JS, Thomas SP, Langdon et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010; 21(6): 1254-1261.
8. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20(12): 1953-1958.
9. Sharma A, Crook T, Thompson A et al. Why biopsying metastatic breast cancer should be routine? Nat Rev Clin Oncol 2010; 7(2): 72-74.
10. Simon R, Nocito A, Hubscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93: 1141-1146.
11. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-1043.
12. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000; 30: 259-265.
13. Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 1230-1235.
14. Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995; 26: 210-216.
15. Cardoso F, Di Leo A, Larsimont D et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001; 12: 615-620.
16. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24: 3032-3038.
17. D'Andrea MR, Limiti MR, Bari M et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 2007; 101(3): 279-284.
18. Gomez-Fernandez C, Daneshbod Y, Nassiri M et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol 2008; 130(6): 879-882.
19. Tsutsui S, Ohno S, Murakami S et al. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur J Surg Oncol 2002; 28(4): 383-387.
20. Carlsson J, Nordgren H, Sjostrom J et al. HER2 expression in breast cancer primary tumours and corresponding metastases. original data and literature review. Br J Cancer 2004; 90(12): 2344-2348.
21. Mori T, Morimoto T, Komaki et al. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 1991; 68(3): 532-537.
22. Brunn RB, Kamby C. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 1989; 185(6): 856-859.
23. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60(2): 252-257.
24. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 1979; 137: 260-262.
25. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 479-485.
26. Mobbs BG, Fish EB, Pritchard KI et al. Estrogen and progesterone receptor content of primary and secondary breast cancer: influence of time and treatment. Eur J Cancer Clin Oncol 1987; 23(6): 819-826.
27. Rasmussen BB, Thorpe SM, Nørgaard T et al. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 1989; 185: 856-859.
28. Hawkins RA, Tesdale AL, Anderson ED et al. Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br J Cancer 1990; 61: 877-880.
29. Li BD, Byskosh A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994; 57(2): 71-77.
30. Umekita Y, Sagara Y, Yoshida H. Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res 1998; 89: 27-32.
31. Kirkegaard T, Edwards J, Tovey S et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48(7): 787-794.
32. Adams EJ, Green JA, Clark AH et al. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999; 52(1): 75-77.
33. van Diest PJ, Weger DR, Lindholm J. Reproducibility of subjective immunoscoring of steroid receptors in breast cancer. Anal Quant Cytol Histol 1996; 18(5): 351-354.
34. Rhodes A, Jasani B, Barnes DM et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-130.
35. Ding L, Ellis MJ, Li S, Larson DE et al. Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 2010; 464(7291): 999-1005.
36. Regitnig P, SchippingerW, LindbauerM et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004; 203(4): 918-926.
37. Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen. Cancer 2005; 104(2): 257-263.
38. Amir E, Clemons M, Freedman OC et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 2010; 28: 15s (Abstr 1007).
39. Karlsson E, Lindström LS, Wilking U et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010; 28: 15s (Abstr 1009).